
argenx SE ARGX
$ 818.82
-1.77%
Annual report 2024
added 01-24-2026
argenx SE Deferred Revenue 2011-2026 | ARGX
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue argenx SE
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 37.8 M | 72.3 M | 2.16 M | 10.1 M | 30.2 M | 4.14 M | 3.45 M | 456 K | 431 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 72.3 M | 431 K | 17.9 M |
Deferred Revenue of other stocks in the Biotechnology industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
86.5 M | - | 2.43 % | $ 254 M | ||
|
Amarin Corporation plc
AMRN
|
2.34 M | $ 14.81 | -0.34 % | $ 6.04 B | ||
|
Acer Therapeutics
ACER
|
2.91 M | - | 2.71 % | $ 14 M | ||
|
I-Mab
IMAB
|
563 K | - | - | $ 866 M | ||
|
Adverum Biotechnologies
ADVM
|
1.85 M | - | - | $ 86.2 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
70.5 K | $ 3.93 | 0.26 % | $ 335 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
6.3 M | - | - | $ 26.5 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
15.9 M | - | - | $ 40.3 B | ||
|
Adagene
ADAG
|
726 K | $ 3.24 | 13.85 % | $ 182 M | ||
|
AlloVir
ALVR
|
2.66 M | - | 4.14 % | $ 49.1 M | ||
|
Midatech Pharma plc
MTP
|
1.3 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.69 M | - | -1.52 % | $ 24.7 M | ||
|
Ampio Pharmaceuticals
AMPE
|
85.7 K | - | -11.43 % | $ 502 K | ||
|
Alterity Therapeutics Limited
ATHE
|
33.3 K | $ 3.48 | -0.98 % | $ 8.37 B | ||
|
Biogen
BIIB
|
55.7 M | $ 195.63 | 0.06 % | $ 28.7 B | ||
|
Acorda Therapeutics
ACOR
|
227 K | - | -24.86 % | $ 820 K | ||
|
Aeglea BioTherapeutics
AGLE
|
517 K | - | - | $ 1.01 B | ||
|
Ascendis Pharma A/S
ASND
|
363 K | $ 216.28 | -0.83 % | $ 5 B | ||
|
Bristol-Myers Squibb Company
BMY
|
510 M | $ 60.51 | 1.12 % | $ 123 B | ||
|
Aravive
ARAV
|
4.41 M | - | -13.39 % | $ 1.45 M | ||
|
Arena Pharmaceuticals
ARNA
|
1.11 M | - | -6.81 % | $ 3.04 B | ||
|
BioNTech SE
BNTX
|
300 M | $ 106.24 | 0.45 % | $ 27.2 B | ||
|
Aridis Pharmaceuticals
ARDS
|
20.2 M | - | 17.91 % | $ 11.1 M | ||
|
Aeterna Zentaris
AEZS
|
2.19 M | - | 5.93 % | $ 314 M | ||
|
Brickell Biotech
BBI
|
1.8 M | - | -5.38 % | $ 6.06 M | ||
|
AgeX Therapeutics
AGE
|
283 K | - | -10.17 % | $ 12.2 K | ||
|
Athersys
ATHX
|
65 K | - | 3.77 % | $ 22.4 M | ||
|
BeiGene, Ltd.
BGNE
|
187 M | - | 0.49 % | $ 251 B | ||
|
AIkido Pharma
AIKI
|
240 K | - | 1.93 % | $ 17.4 M | ||
|
CureVac N.V.
CVAC
|
158 M | - | - | $ 867 M | ||
|
Alpine Immune Sciences
ALPN
|
35.6 M | - | - | $ 2.17 B |